1. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial 
Tsung-Hsien Lee, M.D., Yu-Hung Lin, M.D., Kok-Min Seow, M.D., Jiann-Loung Hwang, M.D., Chii-Ruey Tzeng, M.D., Yu-Shih Yang, M.D., Ph.D. 
Fertility and Sterility 
Volume 90, Issue 1, Pages (July 2008)
DOI: /j.fertnstert
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Flowchart of the structure of the randomized clinical trial analyzing the effectiveness of cetrorelix (Cr) during ovarian stimulation in combination with letrozole (LL) and recombinant FSH.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
Dynamic changes in serum hormone levels (LH, E2, and P) among patients treated with letrozole and recombinant FSH, without (group I) or with cetrorelix (group II). The patients were further stratified according to the occurrence of premature LH surge. ∗,∗∗Significant difference (P<.05 and P<.01, respectively, by Mann-Whitney U test). Vertical bar represents measurement SE. Cr1, Cr2 = first and second administration, respectively, of cetrorelix (0.25 mg) for group II and a leading follicle of >14 mm in diameter for group I; hCG = day of hCG administration.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions